Products - Children and young people | Topic

Showing 18 products

Date | Title

Status: Topic selectionRemove ‘Status: Topic selection’ filter

Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years TS ID 11887
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 18 products

Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]

Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years TS ID 11887

Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766

Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]

Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660

Dupilumab for children with severe atopic dermatitis [TS ID 10434]

Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]

Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002

Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805

Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828

Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

Children and young people Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 18 products

Status
1 selected